Bevacizumab was the first FDA-approved VEGF inhibitor, which is currently approved for therapy of a broad spectrum of human malignancies, including CRC (2004), NSCLC (2006), metastatic breast cancer (2008), GB (2009), renal cell carcinoma (2009), cervical cancer (2014), and ovarian cancer (2018) [222,223,224]. This evidence concerns the gene VEGFA and cervical carcinoma.